Published in Law and Health Weekly, January 27th, 2007
Barr filed an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic version of Thalomid Capsules with the FDA in September 2006. As originally filed, that ANDA sought approval to manufacture and market the 200 mg strength. The company received notification of the application's acceptance for filing from the FDA on December 5, 2006. Following receipt of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.